SCHEMBL24324959

SCHEMBL24324959

CCCCCNc1ccc(CCC)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 1/20 0.47
ABL1 P00519 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
KCNH3 Q9ULD8 1/20 0.45
HRH4 Q9H3N8 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
ESR1 P03372 2/20 0.42
ADRA2A P08913 2/20 0.42
ADORA3 P0DMS8 2/20 0.42
TACR2 P21452 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SHBG P04278 1/20 0.42
TP53 P04637 1/20 0.42
CYP3A4 P08684 1/20 0.42
HSPD1 P10809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28681651 0.90 SPHK1 (0.54) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL28944291 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL28944302 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL13093947 0.90 SPHK1 (0.54) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL8656993 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL28413635 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL21523345 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL22346236 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL21523329 0.90 SPHK1 (0.54) SPHK1ABL1ESR1ADRA2AADORA3
SCHEMBL26666796 0.90 SPHK1 (0.58) SPHK1ABL1ESR1ADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 SPHK1 424/4885ABL1 2605/4885SIGMAR1 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.